RTI Biologics, Inc. (RTIX) Tops Q3 EPS by 1c; Bumps Outlook to High End

RTI Biologics, Inc. (NASDAQ: RTIX) reported Q3 EPS of $0.03, $0.01 better than the analyst estimate of $0.02. Revenue for the quarter came in at $65.2 million versus the consensus estimate of $61.71 million.

RTI Biologics, Inc. sees Q4 2014 EPS of $0.04, versus the consensus of $0.04. RTI Biologics, Inc. sees Q4 2014 revenue of $68-69 million, versus the consensus of $65.13 million.

RTI Biologics, Inc. sees FY2014 EPS of $0.11, versus prior guidance of $0.09-$0.11 and the consensus of $0.1. RTI Biologics, Inc. sees FY2014 revenue of $260-261 million, versus prior guidance of $258-261 million and the consensus of $249.13 million.

“Revenues from the third quarter met our expectations. As anticipated, we saw some impact from seasonality in surgical cases, primarily in international markets, but we were able to offset that with sequential growth in the U.S.,” said Brian K. Hutchison, president and chief executive officer. “We continued to make progress in meeting the goals we shared in our first quarter earnings release – growth in our sports and spine businesses, traction in surgical specialties and expanded distribution of map3® cellular allogeneic bone graft.”

For earnings history and earnings-related data on RTI Biologics, Inc. (RTIX) click here.

You May Also Be Interested In

• BayCom Corp (BCML) Misses Q1 EPS by 4c
• Marten Transport (MRTN) Misses Q1 EPS by 2c
• Elevance Health (ELV) hikes 2024 earnings outlook, shares climb